HCW Biologics Inc (HCWB)

Sorry!
I'm angry

Mmmm

No way, I'm buying hcwb now. There's a reason why we're growing here!
I need to detox!

Hcwb good buy, another one is LBRA
With 65 millions selling agreement for his cmd subsidiary...

Buy now LBRA

2nd tranche went @ $3.23 from .41

Sold 1st tranche @ $3.10 from avg cost of .41 starting in March

too much clementia… 3,3195

$2.85

Still going up $2.34

I can't believe I'm out! I'll come back if they give me a good chance!

1,8399 💪

4.500 holders of record

I added... 17 shares are missing, maybe they act as a barrier

maybe they're cooking something... If anything else good comes out soon... that would be amazing

$HCWB: Helluva Friday....... now $1.20

And its up even though there is a going concern going forward ???


GO $HCWB

****************************************************************


https://investors.hcwbiologics.com/static-files/d727b12a-5adb-41e1-ac90-3a24c9dd09ef

$1.40+ 😃

$HCWB 💹

HCWB............................p/m

$HCWB 💹

Wugen raised $115M and the HCWB deal was suspended — not terminated. If they restart the NK program and reactivate the agreement, the market may realize it priced that optionality at basically zero.

Hopefully they’ll be able to qualify for the PRV — that would be a game changer.

HCW Biologics targets 1H 2027 IND filing for pancreatic cancer T-cell engager HCW11-018b
The purchase of approximately $430,000 by management does not change the fundamentals, but it does signal alignment and makes it less likely that the story is purely narrative without substance.

Lowering quorum doesn’t change the story — it just makes it easier to push it through. What matters now isn’t what comes, but the order: carrots for shorts or cucumbers for bulls.

Added some today @ .31

We are as
in autumn
on the trees
the leaves

https://investors.hcwbiologics.com/static-files/d727b12a-5adb-41e1-ac90-3a24c9dd09ef
HCW Biologics presents a platform-driven immunotherapy company targeting large, high-growth markets at the intersection of inflammation, oncology, and aging.
1. Differentiated Technology Platform
Proprietary fusion-protein platforms (TOBI and TRBC) enable multi-functional biologics, potentially improving efficacy versus single-target therapies and creating a new class of immunotherapeutics.
2. Large and Expanding Addressable Markets
Focused on chronic inflammation-driven diseases, including:
• Autoimmune disorders
• Cancer
• Age-related conditions
These represent multi-billion-dollar markets with unmet need.
3. Diversified Pipeline with Multiple Shots on Goal
• Lead clinical asset (HCW9302) in Phase 1 with broad autoimmune potential
• Preclinical oncology programs targeting limitations of current immunotherapies
• Commercial-ready reagents (HCW9206/9201) enabling near-term monetization via cell therapy manufacturing
This provides both long-term upside and nearer-term revenue optionality.
4. Platform Validation Through Partnerships
Licensing activity (e.g., HCW11-006) demonstrates external validation and creates non-dilutive funding opportunities.
5. Scalable Business Model
Combination of:
• Internal development
• Strategic partnerships / out-licensing
• Enabling tools for cell therapy

The investment case is driven by platform potential and pipeline optionality, balanced against typical early-stage clinical and financing risks.

Thank you, Chuck! keep watching over us from above.

Time only exists as it disappears — and maybe HCWB is the same: a possible illusion, or a fleeting opportunity. But if even 1 in 10 chances is real, by the time that becomes clear, the moment will already be gone. If time only exists as it vanishes, so does opportunity — and when the downside is already realized, the only thing left to fear is missing the moment.

Extremely small float
3–6 million shares

Abnormal volume
hundreds of millions of shares traded
a perfect setup for a squeeze

Narrative setup
strong scientific paper
updated deck ready
discussions with Big Pharma
Wugen deadline approaching

My left hand is itching! I thought, let me see HCWB... but still no news!
However, the value seems compressed to me.

Cucumbers fly!
but isn't it better to short it at $2? if it goes up again and reaches $2 the herd of cattle enters, imo!

Maybe if it sees $2 there is room to stay above $1... how good it would be above $1... it seems that a goad to explode the boil is in the field... but don't sell, don't settle, be greedy!
something seems to be going wrong...

https://investors.hcwbiologics.com/static-files/d727b12a-5adb-41e1-ac90-3a24c9dd09ef

The science is pointing toward IL-7/IL-15/IL-21 as the future of CAR-T — and HCW already has a product built around it.
The real upside isn’t selling a single reagent, but capturing a share of the growing CAR-T reagent market by embedding HCW9206 into manufacturing workflows — where even modest adoption could translate into meaningful recurring revenues, in-house or through licensing.
Why keep it under $1?

https://link.springer.com/article/10.1007/s00262-024-03765-8
https://www.science.org/doi/10.1126/sciadv.aec2632

i added a little🫰

https://investors.hcwbiologics.com/static-files/cc255123-620d-4574-acf7-4cca9fb36313
I wonder Who did they make this for?
With Wugen’s clock ticking toward May, a fresh deck highlighting active Big Pharma discussions and no public-facing events suggests this may be aimed more at a partner than the market.

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic

Only 6 trading days below $1 left before it loses compliance again, right after getting it back.
A carrot for shorts… but possibly a cucumber for bulls. Who knows how this plays out?

Betting they'll announce an offering soon now.

HCW Biologics highlights positive findings for CAR-T therapy manufacturingMarch 16, 2026 10:31 AM
IH Market News
HCW Biologics Inc. (NASDAQ:HCWB) announced new research published in Science Advances indicating that its compound HCW9206 may improve the production of CAR-T cell therapies. The study was carried out by scientists at the Albert Einstein College of Medicine under the direction of Harris Goldstein.According to the research, HCW9206—a multi-cytokine fusion protein—enabled the generation of CAR-T cells with stronger functionality compared with traditional manufacturing methods. In experimental testing, CAR-T cells created using HCW9206 demonstrated anti-tumor effects against leukemia and antiviral activity targeting HIV.The study reported that the compound supports the production of CAR-T cells enriched with long-lasting T-memory stem cells, which represented at least half of the resulting cell population. HCW9206 works by combining the activity of three immune-stimulating cytokines—IL-7, IL-15 and IL-21—within a single molecular scaffold.Conventional CAR-T manufacturing typically relies on anti-CD3/anti-CD28/IL-2-based protocols, which tend to produce CAR-T cells with shorter lifespans. Researchers said HCW9206 could simplify the production process while potentially lowering costs and enhancing the durability and effectiveness of the engineered cells.In studies using humanized mouse models, CAR-T cells produced with HCW9206 showed stronger performance than those manufactured using standard approaches. The experiments evaluated the therapy against both HIV-1 infection—using cells derived from individuals living with HIV—and B-cell leukemia models.HCW Biologics said HCW9206 is a compound ready for commercial development. The company focuses on creating immunotherapy treatments for autoimmune disorders, cancer and diseases linked to aging.The research appeared in Science Advances under the title “IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR-T cells enriched in long-lived T memory stem cells.” Authors included researchers from HCW Biologics, the Albert Einstein College of Medicine, Caring Cross and the University of Texas Southwestern Medical Center.HCW Biologics stock price

Original: HCW Biologics highlights positive findings for CAR-T therapy manufacturing

There are about 3 (to max 6) million shares outstanding, and today’s trading volume has already reached 225 million shares.

A cytokine scaffold combining IL-7, IL-15 and IL-21 generating CAR-T products enriched in T memory stem cells may not be just another academic paper. Sometimes these publications signal a platform shift — particularly when existing licenses are temporarily paused (Wugen).

hcwb..............................................................p/m

If HCW9206 truly enables scalable CAR-T manufacturing enriched with ≥50% T memory stem cells while lowering production costs, it could represent the kind of enabling platform that inevitably attracts Big Pharma attention.
https://link.springer.com/article/10.1007/s00262-024-03765-8

https://investors.hcwbiologics.com/static-files/cc255123-620d-4574-acf7-4cca9fb36313

https://www.nasdaq.com/market-activity/stocks/non-compliant-company-list?page=8&rows_per_page=20